| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.14 | 0.004 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.13 | 0.007 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.097 | 0.05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.09 | 0.05 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.071 | 0.1 |